Cargando…

NLRP3 Inflammasome: A Starring Role in Amyloid-β- and Tau-Driven Pathological Events in Alzheimer’s Disease

Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease commonly diagnosed among the elderly population. AD is characterized by the loss of synaptic connections, neuronal death, and progressive cognitive impairment, attributed to the extracellular accumulation of senile plaques, com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Zeller, Mariana, Dias, Diogo, Sebastião, Ana M., Valente, Cláudia A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543248/ https://www.ncbi.nlm.nih.gov/pubmed/34366341 http://dx.doi.org/10.3233/JAD-210268

Ejemplares similares

JNK Activation in Alzheimer’s Disease Is Driven by Amyloid β and Is Associated with Tau Pathology
por: Solas, Maite, et al.
Publicado: (2023)

NLRP3 inflammasome: The rising star in cardiovascular diseases
por: Zheng, Yidan, et al.
Publicado: (2022)

The NLRP3 inflammasome modulates tau pathology and neurodegeneration in a tauopathy model
por: Stancu, Ilie Cosmin, et al.
Publicado: (2022)

A data-driven study of Alzheimer's disease related amyloid and tau pathology progression
por: Aksman, Leon M, et al.
Publicado: (2023)

The Dichotomy of Alzheimer’s Disease Pathology: Amyloid-β and Tau
por: Ashford, J. Wesson
Publicado: (2019)

Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease
por: Ferrari-Souza, João Pedro, et al.
Publicado: (2022)

The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease
por: Saresella, Marina, et al.
Publicado: (2016)

Aggregated Tau activates NLRP3–ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo
por: Stancu, Ilie-Cosmin, et al.
Publicado: (2019)

Amyloid-β oligomers set fire to inflammasomes and induce Alzheimer's pathology
por: Salminen, Antero, et al.
Publicado: (2008)

The Nlrp3 inflammasome as a “rising star” in studies of normal and malignant hematopoiesis
por: Ratajczak, Mariusz Z., et al.
Publicado: (2020)

Electroacupuncture at ST 36 ameliorates cognitive impairment and beta-amyloid pathology by inhibiting NLRP3 inflammasome activation in an Alzheimer’s disease animal model
por: Ni, Hong, et al.
Publicado: (2023)

NLRP3 and Infections: β-Amyloid in Inflammasome beyond Neurodegeneration
por: Sita, Giulia, et al.
Publicado: (2021)

PHF-Core Tau as the Potential Initiating Event for Tau Pathology in Alzheimer’s Disease
por: Luna-Viramontes, Nabil Itzi, et al.
Publicado: (2020)

The Role of Microglia and the Nlrp3 Inflammasome in Alzheimer's Disease
por: Hanslik, Kendra L., et al.
Publicado: (2020)

Activation of NLRP3 Inflammasome and Onset of Alzheimer’s Disease
por: Bai, Hua, et al.
Publicado: (2021)

Brainstem tau pathology in Alzheimer’s disease is characterized by increase of three repeat tau and independent of amyloid β
por: Uematsu, Miho, et al.
Publicado: (2018)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

BAFF-driven NLRP3 inflammasome activation in B cells
por: Lim, Ken-Hong, et al.
Publicado: (2020)

Amyloid-Driven Tau Accumulation on Mitochondria Potentially Leads to Cognitive Deterioration in Alzheimer’s Disease
por: Cuadrado-Tejedor, Mar, et al.
Publicado: (2021)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology
por: Sandelius, Åsa, et al.
Publicado: (2018)

Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer’s Disease
por: Mullins, Roger J., et al.
Publicado: (2017)

Novel Alzheimer risk genes determine the microglia response to amyloid‐β but not to TAU pathology
por: Sierksma, Annerieke, et al.
Publicado: (2020)

Islet amyloid polypeptide cross-seeds tau and drives the neurofibrillary pathology in Alzheimer’s disease
por: Zhang, Guoxin, et al.
Publicado: (2022)

Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease
por: Bellaver, Bruna, et al.
Publicado: (2023)

Crosstalk Between the NLRP3 Inflammasome/ASC Speck and Amyloid Protein Aggregates Drives Disease Progression in Alzheimer’s and Parkinson’s Disease
por: Hulse, Jonathan, et al.
Publicado: (2022)

Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases
por: Huang, Yi, et al.
Publicado: (2018)

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

NLRP3 Inflammasome and Allergic Contact Dermatitis: A Connection to Demystify
por: Sebastião, Ana Isabel, et al.
Publicado: (2020)

The NLRP6 inflammasome
por: Zheng, Danping, et al.
Publicado: (2020)

NLRP3 inflammasome as a novel therapeutic target for Alzheimer’s disease
por: Zhang, Yun, et al.
Publicado: (2020)

Gender Differences of NLRP1 Inflammasome in Mouse Model of Alzheimer's Disease
por: Zhang, Jinghang, et al.
Publicado: (2020)

Pharmacological and Epigenetic Regulators of NLRP3 Inflammasome Activation in Alzheimer’s Disease
por: La Rosa, Francesca, et al.
Publicado: (2021)

The Role of NLRP3 Inflammasome in Alzheimer’s Disease and Potential Therapeutic Targets
por: Liang, Tao, et al.
Publicado: (2022)

Interaction between autophagy and the NLRP3 inflammasome in Alzheimer’s and Parkinson’s disease
por: Lu, Ranran, et al.
Publicado: (2022)

New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease
por: Park, Sun Ah, et al.
Publicado: (2020)

Nonlinear changes in delayed functional network topology in Alzheimer’s disease: relationship with amyloid and tau pathology
por: Mijalkov, Mite, et al.
Publicado: (2023)

NLRP3 Inflammasome Pharmacological Inhibitors in Glycyrrhiza for NLRP3-Driven Diseases Treatment: Extinguishing the Fire of Inflammation
por: Wang, Zhilei, et al.
Publicado: (2022)

Role of Oxysterols in the Activation of the NLRP3 Inflammasome as a Potential Pharmacological Approach in Alzheimer's Disease
por: Martins, Gabriela L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i96t9btvg2doet0g59omghp8tp